Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 9,367 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Parkinson's Disease
Interventions: Amantadine 300 mg, Topiramate, Sugar Pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Interventions: CTIM-76; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more

Conditions: Respiratory Distress Syndrome
Interventions: Lucinactant for Inhalation, nCPAP alone; Drug · Device
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 29 Weeks to 34 Weeks
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 8 more

Conditions: Hearing Loss, Hearing Impaired Children, Hearing Impairment
Interventions: Audiobooks for hearing loss App; Other
Lead sponsor: BioSpeech; Industry
Eligibility: 9 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, vincristine sulfate, adjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: irinotecan hydrochloride, paclitaxel; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Portland, Oregon

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more

Conditions: Peripheral Neuropathy
Interventions: Low Level Laser, Placebo followed by Low Level Laser; Procedure
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lymphoma, Mantle Cell
Interventions: Acalabrutinib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 65 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 32
States / cities: Tucson, Arizona • Downey, California • Santa Monica, California + 27 more

Conditions: Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions: Ubamatamab, Marlotamig, Sarilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Dexlansoprazole MR; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 181
States / cities: Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more

Conditions: Parkinson's Disease
Interventions: Biofluid samplings, Tissue samplings, DaTSCAN™; Procedure · Drug
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 2 more

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Pancreatic Cancer
Interventions: Ruxolitinib, Placebo, Capecitabine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 153
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 150 more

Conditions: Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, LOPD, Lysosomal Storage Diseases, Acid Maltase Deficiency
Interventions: Neutralizing Antibody to SPK-3006 capsid; Diagnostic Test
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Phoenix, Arizona • Orange, California • Kansas City, Kansas + 3 more

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more

Conditions: Parkinson Disease, Depression
Interventions: paroxetine, venlafaxine, placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 15
States / cities: San Francisco, California • Gainesville, Florida • Miami, Florida + 11 more

Conditions: Type 2 Diabetes
Interventions: SK-0403, Placebo, Sitagliptin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more

Conditions: Bipolar Disorder
Interventions: Ramelteon SL, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 138
States / cities: Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 134 more

Conditions: Pulmonary Embolism and Thrombosis
Interventions: EkoSonic Endovascular System with thrombolytic; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 65
States / cities: Glendale, Arizona • Los Angeles, California • Englewood, Colorado + 54 more

Conditions: Amputation
Interventions: Direct Socket TF; Device
Lead sponsor: Össur Iceland ehf; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 17
States / cities: Mobile, Alabama • Montgomery, Alabama • Opelika, Alabama + 13 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
Interventions: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101; Genetic
Lead sponsor: Vironexis Biotherapeutics Inc.; Industry
Eligibility: 13 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Search by objective public record fields.

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

Audiobooks for Hearing Loss App as Auditory Training

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Systemic Synuclein Sampling Study (S4)

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Study of Antidepressants in Parkinson's Disease

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

An International Pulmonary Embolism Registry Using EKOS

An Investigation Into a New Manufacture Technique of Trans-femoral Sockets

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)